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ORIGINAL ARTICLES
♦ Introduction: Chronic exposure to conventional peritoneal 
dialysis (PD) solutions has been related to peritoneal function 
alterations in PD patients, and associated with mesothelial cell 
loss, submesothelial fibrosis, vasculopathy, and angiogenesis. In 
vitro and ex vivo analyses, as well as studies with animal models, 
have demonstrated that biocompatible PD solutions attenuate 
these morphological alterations. Our aim was to confirm the 
morphological benefits of biocompatible solutions in PD patients.
♦ Methods: We analyzed biopsies from 23 patients treated with 
biocompatible solutions (study group, SG), and compared them 
with a control group (n = 23) treated with conventional solutions 
(CG), matched for time on PD.
♦ Results: A total of 56.5% of SG patients showed total or par-
tial preservation of mesothelial cells monolayer, in contrast with 
26.1% of patients in CG (p = 0.036). Peritoneal fibrosis was not 
significantly less frequent in SG patients (47.8% SG vs 69.6% CG; 
p = 0.13). In patients without previous peritonitis, a significantly 
lower prevalence of fibrosis was present in SG patients (41.7% 
SG vs 77.8% CG; p = 0.04). Hyalinizing vasculopathy (HV) was 
significantly lower in SG (4.3% SG vs 30.4% CG; p = 0.02). Cyto-
keratin-positive fibroblast-like cells were detected in 10 patients 
(22%), but the prevalence was not significantly lower in SG. In the 
univariate regression analysis, the use of biocompatible solutions 
was associated with mesothelial monolayer integrity (p = 0.04) and 
an absence of vasculopathy (p = 0.04). 
♦ Conclusion: The present study demonstrates in vivo in human 
biopsies that biocompatible solutions are better tolerated by 
the peritoneum in the medium and long term than conventional 
solutions.
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Peritoneal membrane failure is among the main limitations for long-term peritoneal dialysis (PD). Chronic exposure 
to conventional PD solutions and peritoneal inflammation 
have been described as the main factors associated with 
peritoneal function alterations in PD patients (1). Loss of 
ultrafiltration has been related to peritoneal morphologi-
cal changes (mesothelial cell loss, submesothelial fibrosis, 
vasculopathy and angiogenesis) (2), although the exact 
morpho-functional correlation has not yet been established. 
It is expected that some peritoneal alterations could be 
prevented or delayed with more biocompatible PD solu-
tions. Indeed, the use of these newer solutions has been 
associated with some clinical benefits, such as delayed 
onset of anuria (3). However, there are conflicting results 
regarding their favorable effects on peritonitis rates (4), 
patient and technical survival, residual renal function, 
and peritoneal membrane function. In vitro and ex vivo 
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analyses, as well as experimental animal studies, have dem-
onstrated that biocompatible PD solutions attenuate some of 
the morphological abnormalities seen with conventional 
solutions (5–7). Due to the difficulties in obtaining perito-
neal biopsies in clinical practice, we still lack confirmatory 
in vivo morphological evidence of the possible benefits of 
biocompatible solutions. The histological information 
regarding peritoneal morphological changes induced by 
this type of fluid in humans is scarce (8–10). In the pres-
ent study, we analyzed biopsies from 23 patients treated 
for variable periods of time with biocompatible solutions, 
and we compared the morphological findings with a con-
trol group treated with conventional solutions matched for 
time on PD.
PATIENTS AND METHODS
STUDY DESIGN AND PATIENTS 
A comparative case-control matched study of biopsies from 
46 PD patients was performed; 23 of them were treated with 
conventional solutions (control group, CG) and 23 with biocom-
patible solutions (study group, SG). We analyzed all available 
biocompatible peritoneal biopsies collected up to September 
2013 in 4 centers, and we compared them with peritoneal 
biopsies from patients under conventional solutions in the 
same time period, matched for time on PD (mean 24.2 ± 18 
months in CG vs 22.7 ± 16 months in SG, p = 0.8) (Figure 1). All 
SG patients used biocompatible solutions from the beginning 
of PD. No biopsy was taken during an inflammatory episode or 
during the following 30 days. In 78% of cases (17 patients in 
CG, 19 in SG), the peritoneal biopsy was performed during kid-
ney transplant surgery. In the remaining 22%, the biopsy was 
obtained during incidental abdominal programmed surgery (in 
CG: 3 nephrectomies, 1 omentectomy, 1 cholecystectomy, and 
1 necropsy; in SG: 2 catheter removals not related to peritoneal 
problems, 1 omentectomy, and 1 polypeptomy).
Clinical characteristics are shown in Table 1. The causes 
of end-stage renal disease were not significantly different 
between the 2 groups (data not shown). Age, gender, and 
diabetes prevalence were similar in both groups (Table 1). 
Patients in SG used automated PD (APD) less frequently than 
CG patients (43.5% SG vs 91% CG, p = 0.001). In CG, 5 patients 
suffered 8 episodes of peritonitis whereas in SG, 11 patients 
had 23 episodes.
SUBGROUP ANALYSIS
We separately performed an analysis according to diabetes 
and peritonitis episodes, designating 3 subsets of patients:
•		 Patients	with	no	peritonitis	episodes	(n = 30) (12 SG, 18 CG) 
•		 Patients	with	previous	peritonitis	episodes	(n = 16) (11 SG, 
5 CG)
•		 Non-diabetic	patients	(n = 41) (20 SG, 21 CG)
PD SOLUTIONS
In SG, 7 patients used Physioneal (Baxter Healthcare 
Corporation, Deerfield, IL, USA), 5 Balance (Fresenius Medical 
Care, Bad Homburg, Germany), 6 BicaVera (Fresenius Medical 
Care, Bad Homburg, Germany) and 5 Selutrio (Fresenius 
Medical Care, Bad Homburg, Germany). In CG, 20 used 
Dianeal (Baxter Healthcare Corporation, Deerfield, IL, USA) 
Figure 1 — Distribution of patients according to time on PD, expressed 
in years, in both groups. 
TABLE 1 
Patient Characteristics at the Time of Peritoneal Biopsy
 Control group Study group
 (n = 23) (n = 23) P
Age (years) 43.8±14 51.5±14 ns
Male gender 12 (52%) 15 (65%) ns
Time on PD (months) 24.2±18 22.7±16 ns
Automated PD  21 (91%) 10 (43.5%) 0.001
Accumulated glucose load (kg) 139.2+151 101.08+110 ns
Diabetes 2 (8.7%) 3 (13%) ns
Peritonitis antecedent  5 (21.7%) 11 (48%) ns
Mean number of peritonitis episodes 1.6±1.3 2.09±1.44 ns
Accumulated days of peritonitis 2.8±2 5.2±4 ns
PD = peritoneal dialysis; ns = not significant.
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and 3 stay•safe (Fresenius Medical Care, Bad Homburg, 
Germany). Icodextrin (Baxter Healthcare Corporation, 
Deerfield, IL, USA) was used by 14 patients (61%) in CG and 
by 5 patients (22%) in SG (p = 0.007).
PERITONEAL SAMPLES
Parietal peritoneal samples were obtained after opening 
the anterior abdominal wall. Biopsy collection and processing 
was done as previously reported (12). Samples were evaluated 
by 2 pathologists without knowledge of clinical data. The 
morphological parameters analyzed were: 
•		 Mesothelial	cell	integrity.	This	was	measured	using	a	semi-
quantitative scale (grade 3 = normal cell density; grade 0 = 
complete denudation), as described by Plum et al. (13).
•		 Submesothelial	 thickness.	 The	 thickness	of	 the	compact	
zone was measured with a micrometer ocular. The mean of 
3 different measures of representative zones was obtained. 
A measurement of less than 150 μm was considered normal 
(Grade 1). A measurement of 150 – 350 μm was considered 
as a moderate thickening (Grade 2). Results greater than 
350 μm were regarded as intense thickening (Grade 3). 
Fibrosis was defined as a submesothelial compact zone 
measuring more than 150 μm (the highest value recorded 
for normal subjects) (10).
•		 Hyalinizing	vasculopathy	 (HV).	 This	was	measured	using	
the 4-grade system described by Honda et al. (14): grade 
0 = no abnormalities; grade 1 = mild thickening without 
stenosis of the lumen; grade 2 = moderate thickening with 
partial luminal stenosis; and grade 3 = intense thickening 
with marked stenosis and luminal distortion or complete 
occlusion. 
•		 In vivo evidence of epithelial-to-mesenchymal transition 
(EMT) (defined by the presence of submesothelial fibro-
blast-like cells expressing cytokeratin) was also evaluated 
as present or absent. 
ETHICAL ISSUES
The procedures were in accordance with the ethical 
standards of the institutional committee on human experi-
mentation and with the Helsinki Declaration of 1975 (revised 
in 1983). All patients gave their informed consent.
STATISTICAL ANALYSIS
Results are given as means ± standard deviation (SD). A 
p value < 0.05 was considered statistically significant. We used 
the non-parametric Mann–Whitney U-test for comparisons 
of means between groups and Fischer’s exact test for com-
parisons of proportions. Univariate and multivariate logistic 
regression analyses were employed to investigate the factors 
associated with the presence of mesothelial cell integrity, 
submesothelial fibrosis, HV, and EMT on peritoneal biopsy. 
All statistical analyses were done using SPSS 14.5 (Chicago, 
IL, USA).
RESULTS
MESOTHELIAL CELL INTEGRITY 
Patients in SG had a significantly greater mesothelial cell 
preservation score than those in CG (mean values 1.78 ± 1.16 vs 
0.91 ± 0.9, p = 0.007). In SG, 56.5% of patients showed total 
or partial preservation of mesothelial cells (score 2 – 3) in 
contrast with 26.1% of patients in CG (p = 0.036) (Figure 2).
To rule out a negative effect of prior inflammation on 
mesothelial preservation, patients without previous peritonitis 
were examined. These patients under biocompatible solutions 
had scores of 2 – 3 more frequently than CG patients (67% 
SG vs 28% CG, p = 0.035). However, patients with peritonitis 
antecedents (n = 16; 11 SG and 5 CG) showed non-significant 
differences (45.5% SG vs 20% CG, p = 0.33), probably due to 
the low number of patients.
Non-diabetic patients, who represent the majority of 
the series, also showed significantly better preservation of 
mesothelial layer among SG (60%) than CG (29%) (p = 0.043).
 
SUBMESOTHELIAL THICKNESS 
Peritoneal fibrosis was less frequent in biocompatible solu-
tion patients, although it did not reach statistical significance 
(47.8% SG vs 69.6% CG, p = 0.13). The average score confirmed 
the lack of significant differences (1.09 ± 1.1 SG vs 1.7 ± 
0.97 CG, p = 0.06). Extreme values of submesothelial thickness 
(> 350 μm) were less common in SG (8.7% vs 17.4%), but again 
differences were not significant.
However, when patients with previous peritonitis were 
excluded, a signif icant lower prevalence of f ibrosis was 
present in SG patients (41.7% SG vs 77.8% CG) (p = 0.04). 
In contrast, these differences did not appear between both 
groups in patients with previous peritonitis (p = 0.59) and in 
non-diabetic patients (p = 0.28). 
Figure 2 — Frequency of patients with different mesothelial preser-
vation score in the 2 groups. Patients using biocompatible solutions 
presented high scores of mesothelial layer preservation much more 
frequently.
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time. In addition, when patients with prior peritonitis episodes 
were excluded, we also found a lower induction of submeso-
thelial fibrosis with biocompatible PD fluids. Improvement of 
these morphological variables (mesothelial integrity, fibrosis, 
and vasculopathy) demonstrates better peritoneal protection 
with the new PD solutions. 
These in vivo findings on PD patients confirm previous in 
vitro and ex vivo studies and experiments in animal models 
showing that biocompatible solutions result in better viabil-
ity of the peritoneal membrane (6–8,15–18), particularly of 
mesothelial cells. Bajo et al. (6) described that in vitro exposure 
of mesothelial cells to conventional fluids resulted in a non-
epithelioid shape and downregulation of E-cadherin, indicative 
of EMT, and in a strong induction of vascular endothelial 
growth factor (VEGF) expression. In contrast, cells in vitro 
exposed to low-GDP solution did not develop these phenotype 
changes. They also observed ex vivo that the prevalence of a 
non-epithelioid phenotype in the conventional group was sig-
nificantly higher with increasing PD duration but, in contrast, 
mesothelial cells from PD effluent of patients treated with 
HYALINIZING VASCULOPATHY
The prevalence of HV was significantly lower in the group 
treated with biocompatible solutions (4.3% SG vs 30.4% CG, 
p = 0.02). The average score was also lower in SG (0.09 ± 0.41 
SG vs 0.48 ± 0.8 CG, p = 0.05). When patients with peritonitis 
were removed, no patients from SG showed HV, in contrast 
with 33.3% from CG (p = 0.025). Patients with prior peritoni-
tis showed similar HV prevalence with both types of solution 
(p = 0.54) (Figure 3). 
Among non-diabetic patients, HV also showed a lower 
prevalence with biocompatible solutions (5% SG vs 28.6% 
CG, p = 0.045).
EPITHELIAL-TO-MESENCHYMAL TRANSITION (SUBMESOTHELIAL 
CYTOKERATIN EXPRESSION)
Evidence of EMT was present in 10 patients (22%), with 
a lower prevalence in SG, but this did not reach statistical 
significance, probably due to the low number of patients 
(13% SG vs 30.4% CG, p = 0.15). Interestingly, when EMT was 
present, mesothelial layer integrity (scores 2 – 3) was never 
present (for both solutions). The incidence of early EMT (less 
than 2 years on PD) did not reach a statistically significant 
difference between the 2 groups (13.3 % SG showed EMT in 
contrast with 33.3% from CG, p = 0.19). 
We also observed a higher prevalence of EMT, although not 
statistically significant, in patients with previous peritonitis 
in both groups (data not shown). Among non-diabetics, a 
lower but also non-significant prevalence of EMT in SG was 
present (p = 0.3).
LOGISTIC REGRESSION ANALYSIS
In the univariate regression analysis, the use of biocompat-
ible solutions was associated with the presence of mesothelial 
cell integrity (odds ratio 3.68; confidence interval 1.06 – 12.7; 
p = 0.04), and continued to be significant after adjusting for 
age, time on PD, and diabetes in the multivariate analysis. 
The significance was lost when accumulated glucose load and 
accumulated days of peritonitis were added to the model. 
In the univariate logistic regression analysis, the use of 
conventional solutions was the only factor that predicted the 
presence of HV (odds ratio 9.62; confidence interval 1.07 – 
86.17; p = 0.04). In the multivariate analysis, its significance 
was lost after adjusting for glucose load.
DISCUSSION 
This study represents the first evidence in vivo of the benefit 
of biocompatible solutions on peritoneal morphology in a short 
series of non-selected PD patients. Peritoneal biopsies from 
patients on PD with biocompatible solutions showed better 
mesothelial cell preservation and lower prevalence of hyalin-
izing vasculopathy when compared with biopsies from patients 
treated with conventional solutions during a similar period of 
Figure 3 — Peritoneal biopsies from patients receiving biocompatible 
solutions (a,c,e) showed better mesothelial cell preservation, less 
submesothelial thickness and hyalinizing vasculopathy when com-
pared with patients treated with conventional fluids (b,d,f). Grade 1 
hyalinizing vasculopathy lesions are seen on image b (arrow). A clear 
contrast among mesothelial cell preservation is evident on all images 
(a,b,c,d: hematoxylin and eosin, ×200). Immunohistochemistry for 
cytokeratins reveals a modified, superficial mesothelial cell (arrow) 
that contrasts with the well preserved layer seen on a biocompatible 
patient (e,f: immunoperoxidase, ×400). 
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low-GDP fluids had fewer signs of EMT. Fernández-Perpén et 
al. (18) also showed that ex vivo mesothelial cells grown from 
effluent of patients treated with bicarbonate/low-GDP fluid 
showed a trend to acquire an epithelial phenotype, with lower 
production of pro-inflammatory cytokines and chemokines 
than those from patients treated with a lactate-buffered con-
ventional PD solution. These 2 studies were released by the 
same group of investigators and are complementary, but very 
consistent. Other studies describing the anatomical alterations 
with biocompatible solutions are scant. In 2005, Do et al. (8) 
reported less ex vivo EMT induction and faster remesothelializa-
tion with low-GDP fluids in a randomized prospective controlled 
study in 60 PD patients, when compared with high-GDP solu-
tions. Ayuzawa et al. (9) showed less peritoneal fibrosis and 
vasculopathy with the use of hybrid therapy, combining PD 
with biocompatible solutions and hemodialysis, in patients 
on PD longer than 3 years. More recently, Kawanishi et al. 
(10) described 12 patients treated with low-GDP neutral solu-
tions who had less peritoneal fibrosis, vascular sclerosis, and 
advanced glycation end-product accumulation, but an increased 
blood capillary density, when compared with 12 patients treated 
with acidic high-GDP solutions. However, the low number of 
patients in the study and the fact that peritoneal specimens 
were obtained during catheter removal, probably due to peri-
toneal membrane problems, make further studies necessary. 
Animal studies have also shown attenuation of peritoneal 
fibrosis and vascularization when biocompatible solutions are 
used. Hekking et al. (19) reported, for the first time, better 
preservation of peritoneal morphology in rats after long-term 
exposure to a bicarbonate/lactate-buffered solution compared 
with a standard solution. This study showed better preserva-
tion of the mesothelial layer and a tendency to lower matrix 
thickness in the biocompatible group. More recently, Mortier 
et al. (20) reported that low-GDP bicarbonate/lactate-buffered 
fluids showed greater peritoneal integrity in rats when com-
pared with conventional PD fluids. 
Another observation from our study is that these mor-
phological benefits may be neutralized by repeated episodes 
of peritonitis. When patients with peritonitis are removed 
from the comparative study, all the morphological variables, 
including fibrosis, show significant differences. It seems 
plausible that peritoneal infections causing inflammation 
modify the peritoneal response to PD fluids, masking their 
potential benefits. In our series, the biocompatible group had 
higher peritonitis prevalence and more accumulated days of 
peritoneal inflammation. Differences in peritonitis may be 
partially related to the higher proportion of patients treated 
with continuous ambulatory PD in the biocompatible group. 
Continuous ambulatory PD implies more manual exchanges 
and a greater risk of peritoneal infection. However, despite a 
greater number of peritonitis episodes, patients treated with 
biocompatible solutions showed less peritoneal damage. We 
found no peritoneal morphological differences among APD 
and continuous ambulatory PD patients. 
Epithelial-to-mesenchymal transition of mesothelial cells 
(conversion into myofibroblasts) has emerged as an important 
contributor to peritoneal damage (21). Part of the protec-
tive effect of biocompatible solutions depends on its greater 
mesothelial preservation and therefore attenuation of EMT. In 
our study, EMT evidence was more prevalent (3 times) among 
patients using conventional solutions, although with a limited 
significance (probably due to the low number of patients, the 
low sensitivity of EMT markers in tissue, and the potential 
confounding factor represented by peritonitis).
Other limitations of the study concern the matching 
procedure. Control group subjects were younger than SG 
subjects and used APD more frequently; these 2 factors are 
intrinsically associated, since younger patients use APD 
more often. The case-control design according to time on 
PD permits the comparisons at equivalent PD duration, a 
well-recognized factor implicated in the morphological 
alterations of peritoneal membrane in the medium to long 
term. The main strength of our study is the large number of 
peritoneal biopsy samples collected, despite the difficulties 
in obtaining them. 
In conclusion, the present study offers in vivo evidence in 
human biopsies that biocompatible solutions are better tol-
erated by the peritoneum in the medium and long term than 
conventional solutions. As a result, we suggest that PD should 
be offered with biocompatible solutions.
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